Koji Haratani

4.0k total citations · 1 hit paper
48 papers, 2.1k citations indexed

About

Koji Haratani is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, Koji Haratani has authored 48 papers receiving a total of 2.1k indexed citations (citations by other indexed papers that have themselves been cited), including 38 papers in Oncology, 29 papers in Pulmonary and Respiratory Medicine and 6 papers in Molecular Biology. Recurrent topics in Koji Haratani's work include Lung Cancer Treatments and Mutations (25 papers), Cancer Immunotherapy and Biomarkers (20 papers) and Lung Cancer Research Studies (11 papers). Koji Haratani is often cited by papers focused on Lung Cancer Treatments and Mutations (25 papers), Cancer Immunotherapy and Biomarkers (20 papers) and Lung Cancer Research Studies (11 papers). Koji Haratani collaborates with scholars based in Japan and United States. Koji Haratani's co-authors include Kazuhiko Nakagawa, Hidetoshi Hayashi, Masayuki Takeda, Kimio Yonesaka, Kaoru Tanaka, Yasutaka Chiba, Ryoji Kato, Hiroyasu Kaneda, Yoshikazu Hasegawa and Keita Kudo and has published in prestigious journals such as Journal of Clinical Investigation, Journal of Clinical Oncology and The EMBO Journal.

In The Last Decade

Koji Haratani

47 papers receiving 2.1k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Association of Immune-Related Adverse Events With Nivolumab Efficacy in Non–Small-Cell Lung Cancer

2017 726 citations Koji Haratani, Hidetoshi Hayashi et al. profile →

Peers

Countries citing papers authored by Koji Haratani

Since Specialization

Citations

This map shows the geographic impact of Koji Haratani's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Koji Haratani with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Koji Haratani more than expected).

Fields of papers citing papers by Koji Haratani

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Koji Haratani. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Koji Haratani. The network helps show where Koji Haratani may publish in the future.

Co-authorship network of co-authors of Koji Haratani

This figure shows the co-authorship network connecting the top 25 collaborators of Koji Haratani. A scholar is included among the top collaborators of Koji Haratani based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Koji Haratani. Koji Haratani is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Identification of key gene signatures for predicting chemo-immunotherapy efficacy in extensive-stage small-cell lung cancer using machine learning 2025 ·Lung Cancer ·Daichi Fujimoto, Ryota Shibaki, Keiichi Kimura, Koji Haratani, Motohiro Tamiya, Takashi Kijima, Yuki Sato, Akito Hata, Toshihide Yokoyama, Yoshihiko Taniguchi, Junji Uchida, Hisashi Tanaka, Naoki Furuya, Satoru Miura, (unknown), Shinya Sakata, Eisaku Miyauchi, Nobuyuki Yamamoto, Yasuhiro Koh, Hiroaki Akamatsu	1
2	Intensity-Modulated Radiotherapy for Locally Advanced Lung Cancer in the Immunotherapy Era: A Prospective Study WJOG12019L 2025 ·JTO Clinical and Research Reports ·Hideyuki Harada, Akito Hata, (unknown), Nobuaki Mamesaya, Kiyoshi Nakamatsu, Koji Haratani, (unknown), Ryota Saito, Hiroshi Mayahara, Masaki Kokubo, Yutaka Satō, Nobuki Imano, Takeshi Masuda, Haruyuki Fukuda, (unknown), Kenichi Yoshimura, (unknown), Kazuhiko Nakagawa, (unknown), Nobuyuki Yamamoto	0
3	Development of a Patient-Derived 3D Immuno-Oncology Platform to Potentiate Immunotherapy Responses in Ascites-Derived Circulating Tumor Cells 2023 ·Cancers ·(unknown), (unknown), Marco Campisi, Minyue Chen, (unknown), Navin R. Mahadevan, Catherine Lee, (unknown), (unknown), Koji Haratani, Zehua Li, Kathleen T Hasselblatt, (unknown), (unknown), Christine G. Lian, Kevin M. Elias, Patrick H. Lizotte, Elena V. Ivanova, David A. Barbie, Daniela M. Dinulescu	3
4	Implication of changes in PD-L1 expression during neoadjuvant chemotherapy with docetaxel, cisplatin, and 5-fluorouracil (DCF) regimen in esophageal squamous cell carcinoma 2022 ·Esophagus ·Seiichiro Mitani, Hisato Kawakami, Osamu Shiraishi, (unknown), Shinichiro Suzuki, Koji Haratani, Hidetoshi Hayashi, Kimio Yonesaka, Yasutaka Chiba, Takushi Yasuda, Kazuhiko Nakagawa	1
5	Mechanisms of primary and acquired resistance to immune checkpoint inhibitors in advanced non–small cell lung cancer: A multiplex immunohistochemistry–based single-cell analysis 2022 ·Lung Cancer ·(unknown), Koji Haratani, Takahiro Tsujikawa, (unknown), Hisato Kawakami, Masayuki Takeda, Kimio Yonesaka, Kaoru Tanaka, Tsutomu Iwasa, Hidetoshi Hayashi, Akihiko Ito, Kazuto Nishio, Kazuhiko Nakagawa	9
6	KRAS Inhibitor Resistance in MET -Amplified KRAS G12C Non–Small Cell Lung Cancer Induced By RAS- and Non–RAS-Mediated Cell Signaling Mechanisms 2021 ·Clinical Cancer Research ·Shinichiro Suzuki, Kimio Yonesaka, Takeshi Teramura, Toshiyuki Takehara, Ryoji Kato, Hitomi Sakai, Koji Haratani, Junko Tanizaki, Hisato Kawakami, Hidetoshi Hayashi, Kazuko Sakai, Kazuto Nishio, Kazuhiko Nakagawa	66
7	A Randomized Phase II Study Comparing Nivolumab with Carboplatin–Pemetrexed for EGFR -Mutated NSCLC with Resistance to EGFR Tyrosine Kinase Inhibitors (WJOG8515L) 2021 ·Clinical Cancer Research ·Hidetoshi Hayashi, Shunichi Sugawara, Yasushi Fukuda, Daichi Fujimoto, Satoru Miura, Keiichi Ota, Yuichi Ozawa, Satoshi Hara, Junko Tanizaki, Koichi Azuma, Shota Omori, Motoko Tachihara, Kazumi Nishino, Akihiro Bessho, Yasutaka Chiba, Koji Haratani, Kazuko Sakai, Kazuto Nishio, Nobuyuki Yamamoto, Kazuhiko Nakagawa	49
8	Successful treatment of a case of hormone receptor–positive metastatic extramammary Paget disease with tamoxifen 2021 ·Investigational New Drugs ·(unknown), Koji Haratani, Satomi Watanabe, Masayuki Takeda, Tsutomu Iwasa, Kazuhiko Nakagawa	1
9	Phase II study of multidisciplinary therapy combined with pembrolizumab for patients with synchronous oligometastatic non-small cell lung cancer TRAP OLIGO study (WJOG11118L) 2021 ·BMC Cancer ·Taichi Miyawaki, Hirotsugu Kenmotsu, Hideyuki Harada, Yasuhisa Ohde, Yasutaka Chiba, Koji Haratani, Tamio Okimoto, Tomohiro Sakamoto, Kazushige Wakuda, Kentaro Ito, Takehiro Uemura, Shinya Sakata, Yoshihito Kogure, Yasumasa Nishimura, Kazuhiko Nakagawa, Nobuyuki Yamamoto	5
10	MO4-5 A multicenter retrospective study of Oncomine Dx Target Test multi-CDx system for genetic profiling of NSCLC: WJOG13019L 2021 ·Annals of Oncology ·Kentaro Ito, Shinya Sakata, Kohei Otsubo, Atsushi Nakamura, Shunsuke Teraoka, N Matsumoto, Yoshimasa Shiraishi, Koji Haratani, Motohiro Tamiya, Satoshi Ikeda, Satoru Miura, Junko Tanizaki, Shota Omori, Hiroshige Yoshioka, Akito Hata, Hisako Yoshida, Nobuyuki Yamamoto, Kazuhiko Nakagawa	1
11	Clinical implications of bronchoscopy for immune checkpoint inhibitor-related pneumonitis in patients with non-small cell lung cancer 2021 ·BMC Pulmonary Medicine ·Osamu Nishiyama, Shigeki Shimizu, Koji Haratani, (unknown), Junko Tanizaki, Hidetoshi Hayashi, Ryo Yamazaki, (unknown), (unknown), Akiko Sano, Kazuhiko Nakagawa, Yuji Tohda	9
12	CAPP-seq analysis of circulating tumor DNA from patients with EGFR T790M–positive lung cancer after osimertinib 2021 ·International Journal of Clinical Oncology ·Ryoji Kato, Hidetoshi Hayashi, Kazuko Sakai, Shinichiro Suzuki, Koji Haratani, Takayuki Takahama, Junko Tanizaki, Yoshikane Nonagase, Kaoru Tanaka, Takeshi Yoshida, Masayuki Takeda, Kimio Yonesaka, Hiroyasu Kaneda, Kazuto Nishio, Kazuhiko Nakagawa	17
13	Impact of EGFR-TKI Treatment on the Tumor Immune Microenvironment in EGFR Mutation–Positive Non–Small Cell Lung Cancer 2020 ·Clinical Cancer Research ·(unknown), Koji Haratani, Hidetoshi Hayashi, Shigeki Shimizu, Shuta Tomida, Takashi Niwa, Toshihide Yokoyama, Yasushi Fukuda, Yasutaka Chiba, Ryoji Kato, Junko Tanizaki, Kaoru Tanaka, Masayuki Takeda, Takashi Ogura, Tadashi Ishida, Akihiko Ito, Kazuhiko Nakagawa	172
14	Severe Immune-Related Hepatitis Treated With Plasma Exchange 2020 ·Journal of Thoracic Oncology ·(unknown), Hidetoshi Hayashi, Satoru Hagiwara, Tomoyuki Otani, Koji Haratani, Kimio Yonesaka, Akihiko Ito, Masatoshi Kudo, Kazuhiko Nakagawa	4
15	Nintedanib promotes antitumour immunity and shows antitumour activity in combination with PD-1 blockade in mice: potential role of cancer-associated fibroblasts 2020 ·British Journal of Cancer ·Ryoji Kato, Koji Haratani, Hidetoshi Hayashi, Kazuko Sakai, Hitomi Sakai, Hisato Kawakami, Kaoru Tanaka, Masayuki Takeda, Kimio Yonesaka, Kazuto Nishio, Kazuhiko Nakagawa	49
16	U3-1402 sensitizes HER3-expressing tumors to PD-1 blockade by immune activation 2019 ·Journal of Clinical Investigation ·Koji Haratani, Kimio Yonesaka, Shiki Takamura, Osamu Maenishi, Ryoji Kato, Naoki Takegawa, Hisato Kawakami, Kaoru Tanaka, Hidetoshi Hayashi, Masayuki Takeda, Naoyuki Maeda, Takashi Kagari, Kenji Hirotani, Junji Tsurutani, Kazuto Nishio, Kazuteru Doi, Masaaki Miyazawa, Kazuhiko Nakagawa	59
17	Clinical and immune profiling for cancer of unknown primary site 2019 ·Journal for ImmunoTherapy of Cancer ·Koji Haratani, Hidetoshi Hayashi, Takayuki Takahama, Yasushi Nakamura, Shuta Tomida, Takeshi Yoshida, Yasutaka Chiba, Takahiro Sawada, Kazuko Sakai, Yoshihiko Fujita, Yosuke Togashi, Junko Tanizaki, Hisato Kawakami, Akihiko Ito, Kazuto Nishio, Kazuhiko Nakagawa	24
18	P3.04-29 Efficacy of Re-Treatment with Immune Checkpoint Inhibitors in Patients with Pretreated Advanced Non-Small Cell Lung Carcinoma 2018 ·Journal of Thoracic Oncology ·Takayuki Takahama, Masayuki Takeda, Koji Haratani, (unknown), Hiroto Hayashi, Kei Nakagawa	2
19	Imaging and clinicopathological features of nivolumab-related cholangitis in patients with non-small cell lung cancer 2017 ·Investigational New Drugs ·Hisato Kawakami, Junko Tanizaki, Kaoru Tanaka, Koji Haratani, Hidetoshi Hayashi, Masayuki Takeda, Ken Kamata, Mamoru Takenaka, Masatomo Kimura, Takaaki Chikugo, Takao Sato, Masatoshi Kudo, Akihiko Ito, Kazuhiko Nakagawa	125
20	Peripheral Blood Biomarkers Associated with Clinical Outcome in Non–Small Cell Lung Cancer Patients Treated with Nivolumab 2017 ·Journal of Thoracic Oncology ·Junko Tanizaki, Koji Haratani, Hidetoshi Hayashi, Yasutaka Chiba, Yasushi Nakamura, Kimio Yonesaka, Keita Kudo, Hiroyasu Kaneda, Yoshikazu Hasegawa, Kaoru Tanaka, Masayuki Takeda, Akihiko Ito, Kazuhiko Nakagawa	182

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact